Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Earnings miss: Neumora reported EPS of ($0.35) for the quarter, missing analysts' consensus of ($0.34) by $0.01.
• Stock and outlook: shares opened at $2.33 and trade in a 12‑month range of $0.61–$3.65 with a market cap of $389.3M; the company shows strong liquidity (current and quick ratios of 6.85) and low leverage (debt/equity 0.15), while consensus analyst sentiment is a Hold with a $6.71 target amid mixed buy/outperform and sell ratings.
• Insider and institutional activity: insider Paul L. Berns sold 9,819 shares at $3.51 (insiders own 26.8% overall and sold 23,387 shares in the past 90 days), and institutional ownership is 47.65% with recent small positions added by HSBC, Virtu, Fred Alger and Barclays increasing its stake.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01), FiscalAI reports.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $2.33 on Monday. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.65. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The stock's 50 day simple moving average is $2.74 and its 200-day simple moving average is $2.32. The firm has a market cap of $389.32 million, a P/E ratio of -1.59 and a beta of 2.46.

Insiders Place Their Bets

In related news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 23,387 shares of company stock valued at $82,647. Company insiders own 26.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth $27,000. Virtu Financial LLC acquired a new position in Neumora Therapeutics during the third quarter worth about $31,000. Fred Alger Management LLC purchased a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $40,000. Public Employees Retirement System of Ohio purchased a new stake in Neumora Therapeutics in the 3rd quarter valued at approximately $44,000. Finally, Barclays PLC raised its holdings in Neumora Therapeutics by 202.0% in the 4th quarter. Barclays PLC now owns 30,924 shares of the company's stock valued at $55,000 after acquiring an additional 20,683 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on NMRA shares. Leerink Partners began coverage on Neumora Therapeutics in a research report on Monday, January 12th. They issued an "outperform" rating and a $8.00 target price for the company. Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. William Blair upgraded shares of Neumora Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, February 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada raised shares of Neumora Therapeutics from a "sector perform" rating to an "outperform" rating and raised their price objective for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Neumora Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $6.71.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.